Suppr超能文献

在进行性肺结核的BALB/c模型中,牛分枝杆菌卡介苗(Mycobacterium bovis BCG)亚菌株对结核分枝杆菌感染提供不同程度的保护。

Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis.

作者信息

Castillo-Rodal Antonia Isabel, Castañón-Arreola Mauricio, Hernández-Pando Rogelio, Calva Juan José, Sada-Díaz Eduardo, López-Vidal Yolanda

机构信息

Programa de Inmunología Molecular Microbiana, Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Circuito Escolar S/N, 04510 México, D.F., México.

出版信息

Infect Immun. 2006 Mar;74(3):1718-24. doi: 10.1128/IAI.74.3.1718-1724.2006.

Abstract

Mycobacterium bovis BCG is the only available vaccine against tuberculosis. Reasons for why diverse BCG substrains induce different levels of protection in clinical trials remain unclear. The aim of this study was to compare the effectiveness of 10 BCG substrains in a mouse model of pulmonary tuberculosis. BALB/c mice were subcutaneously vaccinated and 2 months later were challenged with Mycobacterium tuberculosis H37Rv by intratracheal injection. Two and 4 months after challenge, delayed-type hypersensitivity (DTH) response, lung tissue affected by pneumonia, CFU, T-cell counts, and cytokine expression (interleukin-2 [IL-2], IL-4, IL-10, and gamma interferon) were determined. A differential protective effect of the diverse BCG substrains was found. BCG Phipps led to the largest and most persistent reduction of CFU counts and of the area of pneumonia at 2 and 4 months after challenge. This protection was accompanied by reduced IL-10-producing T cells. Contemporary BCG substrains induce a wide range of protection in this animal model. These data can help in the selection of the best vaccine for human immunization and for the development of novel recombinant BCG-based vaccine.

摘要

牛分枝杆菌卡介苗(Mycobacterium bovis BCG)是唯一可用的抗结核疫苗。不同卡介苗亚菌株在临床试验中诱导不同程度保护作用的原因尚不清楚。本研究的目的是在肺结核小鼠模型中比较10种卡介苗亚菌株的有效性。对BALB/c小鼠进行皮下接种,2个月后通过气管内注射用结核分枝杆菌H37Rv进行攻击。攻击后2个月和4个月,测定迟发型超敏反应(DTH)、受肺炎影响的肺组织、菌落形成单位(CFU)、T细胞计数和细胞因子表达(白细胞介素-2 [IL-2]、IL-4、IL-10和γ干扰素)。发现不同卡介苗亚菌株具有不同的保护作用。卡介苗菲普斯株(BCG Phipps)在攻击后2个月和4个月导致CFU计数和肺炎面积最大且最持久的减少。这种保护作用伴随着产生IL-10的T细胞减少。当代卡介苗亚菌株在该动物模型中诱导出广泛的保护作用。这些数据有助于选择用于人类免疫的最佳疫苗以及开发新型重组卡介苗疫苗。

相似文献

2
A new vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis.
Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):115-26. doi: 10.1016/j.tube.2004.10.004. Epub 2005 Jan 22.
5
[Novel vaccines against M. tuberculosis].
Kekkaku. 2006 Dec;81(12):745-51.
9
Loss of anti-mycobacterial efficacy in mice over time following vaccination with Mycobacterium bovis bacillus Calmette-Guérin.
Vaccine. 2011 Sep 16;29(40):6881-7. doi: 10.1016/j.vaccine.2011.07.051. Epub 2011 Jul 29.

引用本文的文献

3
The Mycobacterium tuberculosis genome at 25 years: lessons and lingering questions.
J Clin Invest. 2023 Oct 2;133(19):e173156. doi: 10.1172/JCI173156.
5
A Current Perspective on the Potential of Nanomedicine for Anti-Tuberculosis Therapy.
Trop Med Infect Dis. 2023 Feb 3;8(2):100. doi: 10.3390/tropicalmed8020100.
6
Advance in strategies to build efficient vaccines against tuberculosis.
Front Vet Sci. 2022 Nov 24;9:955204. doi: 10.3389/fvets.2022.955204. eCollection 2022.
9
The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview.
Front Microbiol. 2021 Oct 21;12:757858. doi: 10.3389/fmicb.2021.757858. eCollection 2021.

本文引用的文献

2
A new vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis.
Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):115-26. doi: 10.1016/j.tube.2004.10.004. Epub 2005 Jan 22.
3
A second-generation anti TB vaccine is long overdue.
Ann Clin Microbiol Antimicrob. 2004 Jun 3;3:10. doi: 10.1186/1476-0711-3-10.
4
Recent progress in the development and testing of vaccines against human tuberculosis.
Int J Parasitol. 2003 May;33(5-6):547-54. doi: 10.1016/s0020-7519(03)00061-4.
5
WHO annual report on global TB control--summary.
Wkly Epidemiol Rec. 2003 Apr 11;78(15):122-8.
8
Optimal models to evaluate the protective efficacy of tuberculosis vaccines.
Tuberculosis (Edinb). 2001;81(1-2):133-9. doi: 10.1054/tube.2000.0271.
9
Correlation between BCG genomics and protective efficacy.
Scand J Infect Dis. 2001;33(4):249-52. doi: 10.1080/003655401300077180.
10
BCG: the challenge continues.
Scand J Infect Dis. 2001;33(4):243-5. doi: 10.1080/003655401300077144.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验